New cell culture plate eliminates edge effect during extended incubation
Thermo Scientific Nunc Edge 2.0 plate is designed to cost effectively increase cell consistency and productivity in cell-based assays.
A new 96-well plate is uniquely engineered to virtually eliminate evaporation during lengthy incubation, enabling full-plate usage and increased well-to-well cell consistency for improved productivity in cell culture assays at a cost comparable to a standard 96-well plate.
The Thermo Scientific Nunc Edge 2.0 96-Well Plate features a surrounding moat that, when filled with sterile water or media, serves as an evaporation barrier during extended incubation. As a result, edge effect and its associated risks of heterogeneous or biased results decrease. Even after long incubation periods of up to four days, the overall plate evaporation rate is reduced to less than two percent. More samples per plate can therefore be analyzed, increasing assay performance with potentially less cost and related product waste. Due to its large evaporation buffer zones, the next generation Nunc Edge 2.0 96-Well Plate is designed to eliminate well-to-well variability for optimal cell consistency across all of its 96 wells.
“When it comes to growing healthy, viable cells in extended microplate cultures, evaporation is a common yet significant challenge that researchers face,” explains Norman Yung, vice president and general manager, labware and specialty plastics at Thermo Fisher Scientific. “To minimize evaporation and mitigate its negative effects, researchers typically avoid using the outer wells of a standard 96-well plate, ultimately sacrificing 37.5% of the plate’s available real estate. With our new Edge 2.0 plate, scientists can reclaim full use of their plate without having to worry about edge effect. Researchers can also plan their experiments more efficiently and benefit from potential cost savings as a result of using and discarding fewer plates per experiment. We are also pleased to offer the new Edge 2.0 plate at a comparable price to a standard 96-well plate, enabling researchers to benefit from this innovation without compromising tight budgets.”
The new 96-well Edge 2.0 plate is available with both cell culture-treated and non-treated surfaces to suit an extensive range of lab applications. Untreated surfaces allow researchers to add the required coatings themselves, while also being hydrophobic and thus appropriate for growth of suspension cultures that can proliferate and grow without attachment. Conversely, the certified culture-treated option is designed to facilitate cell attachment and growth and is ideal for applications with adherent cell cultures.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.